Vir Biotechnology (VIR) accounting chief sells 7,711 shares under plan

Rhea-AI Filing Summary

Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini sold 7,711 shares of common stock in an open‑market transaction at a price of $9.12 per share on March 23, 2026. The filing shows he directly holds 61,902 shares after this sale. According to a footnote, the transaction was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 19, 2025, indicating it was scheduled in advance as part of a trading program.

Insider Trade Summary 10b5-1

Net Seller: 7,711 shares ($70,324)

Net Sell 1 txn

Insider Sabatini Brent

Role SVP, Chief Accounting Officer

Sold 7,711 shs ($70K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,711	$9.12	$70K

Holdings After Transaction: Common Stock — 61,902 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabatini Brent

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		S(1)		7,711	D	$9.12	61,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Vir Biotechnology (VIR) report for Brent Sabatini?

Vir Biotechnology reported that Brent Sabatini sold 7,711 shares of common stock. The open‑market sale occurred on March 23, 2026, at $9.12 per share and was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 19, 2025.

At what price were Brent Sabatini’s Vir Biotechnology (VIR) shares sold?

Brent Sabatini’s shares were sold at $9.12 per Vir Biotechnology share. The Form 4 states this price for the 7,711 common shares sold in an open‑market transaction on March 23, 2026, under a previously adopted Rule 10b5‑1 trading plan.

How many Vir Biotechnology (VIR) shares does Brent Sabatini hold after the sale?

After the reported sale, Brent Sabatini directly holds 61,902 Vir Biotechnology common shares. This post‑transaction balance is disclosed in the Form 4 and reflects his remaining direct ownership following the 7,711‑share open‑market sale on March 23, 2026.

Was the Vir Biotechnology (VIR) insider sale made under a Rule 10b5-1 plan?

Yes, the sale was executed under a Rule 10b5‑1 trading plan. A footnote explains that Brent Sabatini adopted this plan on December 19, 2025, meaning the 7,711‑share sale on March 23, 2026, was pre‑scheduled rather than a spontaneous market decision.

Who is the insider involved in the latest Vir Biotechnology (VIR) Form 4 filing?

The insider is Brent Sabatini, Vir Biotechnology’s senior vice president and chief accounting officer. The Form 4 shows his open‑market sale of 7,711 common shares at $9.12 on March 23, 2026, and confirms he directly owns 61,902 shares afterward.